U.S. Metals and Mining Stock News

Renasant stock snapshot after recent performance shift Renasant (RNST) has drawn fresh attention after a recent shift in its share performance, with the stock showing mixed short term moves but double digit gains over the past month and past 3 months. See our latest analysis for Renasant. At the current share price of $39.40, Renasant has seen a 1 day share price return of 0.86% decline, while its recent 30 day share price return of 10.49% and 1 year total shareholder return of 45.91% reflect...

Earlier this week, BTIG Research initiated analyst coverage on Evergy with a Buy rating, citing substantial earnings growth potential and a supportive regulatory backdrop in its Midwestern service territories. The coverage highlights how Evergy’s earnings profile could eventually warrant a premium valuation within the utility sector if its growth plans materialize as expected. We’ll now examine how BTIG’s emphasis on Evergy’s earnings growth prospects interacts with the existing investment...

In recent days, multiple research firms including Keefe, Bruyette & Woods, Barclays and Wells Fargo have updated their views on Corebridge Financial, largely reaffirming positive ratings such as “Outperform” and “Overweight” while revising their assessments of the company’s outlook. This cluster of analyst actions highlights sustained institutional interest in Corebridge’s business model and market position, even as opinions on its prospects are being recalibrated. Next, we’ll examine how...

We wouldn't blame Box, Inc. ( NYSE:BOX ) shareholders if they were a little worried about the fact that Eliahu...

Sales update and leadership change draw attention to Buckle (BKE) Buckle (BKE) has drawn fresh investor attention after reporting higher comparable store and total net sales for recent 5 week and 9 week periods, alongside appointing longtime executive Scott A. Werth as Senior Vice President of Stores. See our latest analysis for Buckle. Buckle’s recent sales update and leadership change arrived after a mixed share price pattern, with a 9.4% 7 day share price return and a 71.3% 1 year total...

On 1 April 2026, IDEXX Laboratories launched the IDEXX Cancer Dx Panel in the UK, offering a blood-based test for early detection of lymphoma in at-risk dogs via its reference laboratories, with results available in 3–5 business days and veterinarian pricing starting from £22.50. The UK introduction builds on adoption by nearly 6,000 practices in North America and underscores IDEXX’s push to embed cancer screening into routine preventative care, supported by research showing strong pet owner...

Considering whether Transocean at US$6.52 still offers value after a strong run, or whether most of the upside is already reflected in the price. The stock has seen mixed short term moves, with a 1.1% decline over the last 7 days and a 2.5% gain over 30 days, while the year to date return sits at 53.8% and the 1 year return at 188.5%. Recent coverage has focused on Transocean as an offshore drilling contractor and how sentiment around the sector, contract activity, and balance sheet...

In recent days, Atour Lifestyle Holdings reported a fourth-quarter earnings beat that pointed to stronger-than-expected business momentum, coinciding with easing geopolitical tensions after a U.S.-Iran ceasefire that supported travel and consumer names. An interesting aspect is how this combination of robust operating performance and lower oil-related macro risk has drawn in both fundamental and technically focused investors eyeing the company’s operating profile. We’ll now examine how this...

In recent days, Palomar Holdings has drawn fresh attention from Wall Street as analysts reaffirmed favorable ratings, highlighted its underwriting performance, and pointed to strong institutional interest in the specialty insurer. At the same time, governance updates, insider share sale disclosures, and the closing of a new US$450,000,000 credit facility provide investors with additional context on how Palomar is managing risk, growth, and executive incentives. With analysts reinforcing...

Sabine Royalty Trust recently reported April 2026 production results, with oil volumes of 44,645 bbls and gas volumes of 885,409 Mcf, both slightly below the prior month, and declared a monthly cash distribution of US$0.324970 per unit payable on April 29, 2026. This combination of updated production data and a confirmed April payout gives investors a clearer snapshot of the trust’s current income profile. We’ll now look at how the latest monthly distribution declaration shapes Sabine...

In recent months, IQVIA has rolled out its IQVIA.ai platform in partnership with NVIDIA, acquired drug discovery assets from Charles River Laboratories, and expanded research collaboration with the Duke Clinical Research Institute, while also being ranked the top company on the 2026 Fortune World’s Most Admired Companies List for the fifth consecutive year. Together, these AI-focused initiatives and partnerships underline how IQVIA is weaving advanced computing into regulated life sciences...

In recent days, McKesson has drawn attention as multiple analysts revised their outlooks and the company announced the upcoming retirement of long-time CFO Britt Vitalone, with Kenny Cheung set to assume the role in May 2026. This combination of shifting views on its earnings drivers and a leadership transition in the finance seat has sharpened investor focus on how resilient McKesson’s business model really is. Against this backdrop of analyst reassessments and a CFO transition, we’ll...

In February 2026, Danaos Corporation reported earnings per share of 7.14 and revenue of US$266.26 million, both ahead of analyst expectations. The twin surprises in profit and sales highlight how Danaos’s containership fleet is currently converting charter demand into stronger-than-forecast financial results. With this earnings beat as a backdrop, we’ll now examine how stronger-than-expected profitability reshapes Danaos’s existing investment narrative. AI is about to change healthcare...

Investors may be wondering whether Capri Holdings shares still offer value after a turbulent few years, or if most of the opportunity is already reflected in the current price. The stock last closed at US$19.88, with returns of 10.7% over 7 days, 7.0% over 30 days, an 18.5% decline year to date and a 35.7% gain over the past year, while 3 and 5 year returns stand at 55.3% and 63.1% declines respectively. Recent price moves have come as investors reassess the brand portfolio and the broader...

Curtiss-Wright recently reported that over the past two years it has delivered 10.9% annual revenue growth, a 16.9% operating margin, and 18.8% annual earnings per share growth, reflecting efficient operations and the impact of share buybacks. At the same time, analysts have raised their earnings estimates and assigned Curtiss-Wright a strong growth-focused rating, suggesting that its operational efficiency and capital returns are increasingly central to how the business is being...

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...

If you are wondering whether Futu Holdings at US$154.50 is still reasonably priced after a strong run, the next sections will focus squarely on what the current share price might imply about value. The stock has returned 10.2% over the past week and 9.5% over the past month, with a 92.2% return over the last year but a 13.4% decline year to date and a 230.6% return over three years and 3.3% over five years. Recent coverage has highlighted Futu Holdings as a prominent online brokerage play...

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...

Freshworks (NasdaqGS:FRSH) appointed Kuntal Vahalia as Senior Vice President, Partnership Channel. Vahalia will lead the company’s global partner strategy with a focus on the partner channel. The role includes supporting Freshworks’ efforts to move further upmarket and deepen ties with global system integrators. For investors tracking SaaS platforms, Freshworks operates in the customer and employee experience software space, where partner ecosystems often influence how quickly products...

Five Below (NasdaqGS:FIVE) reported strong quarterly results, with revenue and earnings exceeding analyst expectations. The company opened a new store in Corbin, Kentucky, adding to its growing brick and mortar footprint. Management, led by CEO Winnie Park, highlighted ongoing progress on key business initiatives alongside the latest store launch. Five Below enters this update cycle with its shares at $217.37 and a very large 1 year return of 259.5%. The company has also recorded a 12.4%...

If you are wondering whether Winmark at around US$444 per share offers good value or if you might be arriving late, this piece lays out the key facts so you can judge the price for yourself. The stock has recently moved 3.2% over the last 7 days, with a 1 year return of 37.5% and 10.6% year to date. The 30 day return sits at a 1.2% decline and the 3 and 5 year returns are 46.1% and 163.2% respectively. Recent attention around Winmark has focused on its position in the Specialty Retail space...

If you are wondering whether Ventas at around US$84.96 is offering fair value or a stretched price, you are in the right place for a clear valuation breakdown. The stock has returned 2.0% over the last week, 9.9% year to date and 32.0% over the past year. Over the last 30 days it has declined 1.8%, which may have shifted some investors' sense of risk and opportunity. Recent coverage has focused on Ventas in the context of its role as a health care focused REIT, with attention on how its...

Anbio Biotechnology, NasdaqGM:NNNN, is expanding beyond COVID-19 diagnostics into a broader test portfolio. The company is rolling out new rapid immunoassay and PCR platforms across human health, veterinary, and multi-disease applications. This move reflects a business model shift toward more diversified diagnostic revenues and reduced reliance on legacy COVID-19 products. For you as an investor, this repositioning matters because Anbio Biotechnology is moving from a single product focus...